
A series of recently published large-scale and independent meta-analyses have confirmed Favipiravir to be effective against mild to moderate COVID-19 DE – April 28th, 2022 – Cellvera, a US biopharmaceutical company, today reports a summary of recent studies demonstrating the efficacy of Favipriavir against several SARS-CoV-2 variants, including Delta and Omicron, and findings from the […]